Bayer Reports Landmark Year with Five Pivotal Drug Approvals, Accelerates Growth Strategy Across Oncology and Cardiovascular Medicine
核心洞察
Bayer achieved five pivotal worldwide drug approvals in 2025, marking a landmark year of strategic execution for its pharmaceutical division.
The company's cardiovascular portfolio expanded with asundexian meeting primary endpoints in the Phase III OCEANIC-STROKE (搜索) study for secondary stroke prevention.
Oncology growth accelerated with FDA approval of Hyrnuo (搜索) (sevabertinib (搜索)) for HER2 (搜索)-mutant non-small cell lung cancer (搜索) and continued success of Nubeqa (darolutamide).
Bayer AG announced significant momentum in its pharmaceutical growth strategy at the 44th J.P. Morgan Healthcare Conference, highlighting five pivotal worldwide approvals achieved in 2025 and outlining ambitious expansion plans across oncology, cardiology, and women's health. The German pharmaceutical giant reported successful execution of its strategic vision, with multiple high-impact launches cementing the division's growth trajectory for coming years.
"We are now clearly seeing the success of our strategy. We have fundamentally accelerated Bayer Pharmaceutical's growth runway with multiple high-impact launches across oncology, cardiology, and women's health," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer's Pharmaceuticals Division.
Cardiovascular Pipeline Advances with Breakthrough Stroke Prevention Data
Bayer's cardiovascular portfolio achieved a significant milestone with asundexian, an investigational once-daily oral Factor XIa (搜索) inhibitor, meeting its primary safety and efficacy endpoints in the Phase III OCEANIC-STROKE (搜索) study. The trial represents the first successfully completed Phase III study of a Factor XIa inhibitor, underscoring the blockbuster potential of asundexian in secondary stroke prevention.
The clinical need for improved stroke (搜索) prevention remains substantial, with approximately 12 million people worldwide experiencing a stroke annually. Of these cases, 20-30% represent recurrent strokes, and despite available secondary prevention options, one in five stroke survivors will experience another stroke within five years. Stroke ranks as the second leading cause of death globally, with recurrent ischemic strokes typically proving more disabling and carrying higher mortality risk than initial events.
Asundexian has received Fast Track Designation from the U.S. Food and Drug Administration as a potential treatment for stroke (搜索) prevention in patients after non-cardioembolic ischemic stroke.
The company also expanded its cardiovascular reach through regulatory approvals of finerenone (Kerendia) for patients with heart failure (搜索) with left ventricular ejection fraction of ≤40%. The FDA and Japan's Ministry of Health, Labour and Welfare approved the indication based on positive results from the pivotal Phase III FINEARTS-HF study, building on the drug's established efficacy in chronic kidney disease associated with type 2 diabetes.
Oncology Portfolio Delivers Commercial Success and Pipeline Progress
Bayer's oncology division demonstrated robust performance, led by the continued global uptake of blockbuster Nubeqa (darolutamide), which has treated over 200,000 patients worldwide. The prostate cancer (搜索) treatment achieved a third approval in both the U.S. and Europe, with total global sales rising across all markets. A third approval in China is anticipated for 2026, while the comprehensive clinical development program explores Nubeqa's potential in earlier prostate cancer settings, with two additional Phase III readouts expected in 2027 and 2028.
The FDA granted accelerated approval for Hyrnuo (搜索) (sevabertinib (搜索)) for adult patients with locally advanced or metastatic non-squamous HER2 (搜索)-mutant non-small cell lung cancer (搜索) who have received prior systemic therapy. The approval followed Breakthrough Therapy Designations from both the FDA and China's CDE, based on results from the SOHO-01 study. Sevabertinib addresses unmet needs for a patient population with limited treatment options.
Bayer's targeted radionuclide therapy leadership continued with positive results from the EORTC PEACE III study evaluating radium-223 dichloride (Xofigo) in combination with enzalutamide, which met its primary endpoint. An additional Phase III clinical study with radium-223 dichloride will be completed in 2026 to guide future regulatory decisions.
Women's Health Breakthrough with Hormone-Free Menopause Treatment
The company achieved a significant advancement in women's health with regulatory approvals of Lynkuet (elinzanetant) for treating moderate to severe vasomotor symptoms due to menopause (搜索). Lynkuet represents the only hormone-free therapy approved in the EU for both moderate to severe vasomotor symptoms associated with menopause or caused by adjuvant endocrine therapy for breast cancer. The approvals followed consistent positive results across all four Phase III clinical studies (OASIS 1-4).
Cell and Gene Therapy Portfolio Gains Momentum
Bayer's cell and gene therapy portfolio received multiple regulatory priority designations from authorities in the U.S., Europe, and Japan. Bemdaneprocel, an investigational cell therapy designed to replace dopamine-producing neurons lost in Parkinson's disease (搜索), entered pivotal evaluation in a Phase III study through Bayer's wholly owned subsidiary BlueRock Therapeutics (搜索).
AskBio's ametefgene parvec (AB-1005), an investigational gene therapy, is being assessed in a Phase II study for moderate-stage Parkinson's disease (搜索), with the first participant randomized in Germany and recruitment ongoing in the U.S., UK, and Poland.
Expanding Diagnostic Capabilities
Bayer continues advancing medical imaging innovation with gadoquatrane, an investigational low-dose MRI contrast designed to reduce gadolinium dose by up to 60% compared to other macrocyclic MRI contrast agents. Building on positive Phase III results, the company submitted marketing authorization applications in key markets worldwide, including the U.S., EU, Japan, and China.
The company announced strategic acquisition of two investigational radiotracers – AT-01 (a PET tracer in Phase III development) and AT-05 (a SPECT tracer in Phase I) – for cardiac amyloidosis diagnosis, marking Bayer's entry into diagnostic tracers and expansion in molecular imaging.
With fiscal 2024 sales of 46.6 billion euros and R&D expenses of 6.2 billion euros, Bayer employed approximately 93,000 people globally, positioning the company for continued growth across its diversified pharmaceutical portfolio.